Published by:

Dyslipidaemia (elevated triglycerides, low high-density lipoprotein-cholesterol [HDL-C] and anincrease in small, dense low-density lipoprotein [LDL] particles) is an important contributor to the increased cardiovascular risk associated with type 2 diabetes. Lowering LDL-C levels with a statin is the main focus of lipid-modifying intervention. Fibrates are effective against all components of this atherogenic mixed dyslipidaemia. Adding a fibrate to primary statin therapy is a logical approach to achieving all lipid targets. Evidence from the Fenofibrate Invention and Event Lowering in Diabetes trial also shows that fenofibrate is a well-tolerated option with potential benefits on the progression of microvascular complications of type 2 diabetes. Thus fenofibrate-statin combination therapy may translate into greater reductions in vascular risk. Br J Diabetes Vasc Dis 2008;8:22-7 Key words: cardiovascular risk, dyslipidaemia, efficacy, fenofibrate, safety, type 2 diabetes